AQST•November 17, 2026 at 1:17 AM UTCPharmaceuticals, Biotechnology & Life Sciences

AQST: Anaphylm FDA Date Slips to 2027, Extending Cash Burn and Risk

Read source article

What happened

Aquestive Therapeutics announced at the Jefferies conference that the FDA decision on Anaphylm is now expected on March 16, 2027, a significant delay from the previously anticipated January 31, 2026 PDUFA date. This pushes the company's primary catalyst out by over a year, compounding its already precarious financial position highlighted in the master report, which includes negative stockholders' equity and declining legacy revenue. Management's emphasis on 'preparing for launch' obscures the reality that they are still awaiting regulatory clarity, and the delay suggests potential issues with the NDA or a complete response letter. Meanwhile, competitive pressure from ARS Pharmaceuticals' neffy nasal spray continues to erode the needle-free epinephrine opportunity, and the extended timeline increases the need for additional capital. Overall, the news aligns with the bear case from the master report, which assigned a 40% probability to a delayed or restricted approval, and now that delay appears materialized.

Implication

The one-year delay in the FDA decision reduces the present value of Anaphylm's future cash flows and raises the probability of further equity issuance or distressed financing, given the company's $167.7M in liabilities and ongoing cash burn. With the PDUFA now set for March 2027, Aquestive will need to fund another year of operating losses and launch preparations without the revenue offset management had previously guided. The competitive environment worsens as neffy gains further market share and payer relationships, making Anaphylm's eventual commercial ramp more challenging and less lucrative. Investors should reassess the base-case probability of approval and successful commercialization, as the delay may reflect unresolved FDA concerns about the product's PK/PD profile or manufacturing. Until clarity emerges on the reasons for the delay and the company's funding strategy, the stock's risk-reward remains unfavorable for new money, and existing holders should consider trimming positions.

Thesis delta

The thesis shifts from 'binary PDUFA with unfavorable payoff' to 'extended binary risk with heightened funding uncertainty.' The master report's bear scenario (40% probability) anticipated FDA constraints or delays, and the news confirms that scenario is playing out. This strengthens the case for a lower fair value and reinforces the 'POTENTIAL SELL' rating, though the exact impact depends on whether the delay is a simple extension or a signal of deeper regulatory issues.

Confidence

medium